GHRP-6
GHRP-6 is a peptide, indexed here under Growth hormone secretagogues.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Growth hormone secretagogues |
| CAS registry number | Unknown No CAS-format synonym was present on the retrieved PubChem record. |
| PubChem CID | 4345065[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C46H56N12O6[1] |
| Molecular weight | 873 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
GHRP-6 is a hexapeptide growth hormone secretagogue. A 2001 Molecular Endocrinology paper examines regulation of Pit-1 expression by ghrelin and GHRP-6 through the growth hormone secretagogue receptor. Human endocrine studies in the retrieved set include a 1993 and a 1995 Journal of Clinical Endocrinology and Metabolism report on growth hormone secretion after combined administration with growth hormone releasing hormone.
Non-endocrine endpoints also appear: a 2005 European Journal of Pharmacology comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats, and a 2014 paper in Alcoholism, Clinical and Experimental Research using a GHRP-6 derived ghrelin antagonist.
[3, 4, 5, 6, 7]Reported mechanism
Acts through the growth hormone secretagogue receptor, the ghrelin receptor.
[3]Stated in the title of the cited 2001 Molecular Endocrinology paper.
Targets named in the cited records: growth hormone secretagogue receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
GHRP-6 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- growth hormone releasing peptide 6
Where this page sits
Research records
Cited research records for GHRP-6, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include GHRP-6
Compounds indexed next to it
- Ipamorelin — Growth hormone secretagogues
- Hexarelin — Growth hormone secretagogues
- Ibutamoren — Growth hormone secretagogues
- Ghrelin — Growth hormone secretagogues
- GHRP-2 — Growth hormone secretagogues
Named targets in the cited records
Class page: Growth hormone secretagogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for GHRP-6?
GHRP-6 is a hexapeptide growth hormone secretagogue. A 2001 Molecular Endocrinology paper examines regulation of Pit-1 expression by ghrelin and GHRP-6 through the growth hormone secretagogue receptor.
Which class is GHRP-6 indexed under?
GHRP-6 is indexed under Growth hormone secretagogues. Growth hormone secretagogues are compounds that act at the growth hormone secretagogue receptor, the receptor for ghrelin, rather than at the growth hormone releasing hormone receptor.
What does the FDA application register show for GHRP-6?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 4345065, Ghrp-6. PubChem, National Library of Medicine (2026). pubchem:4345065
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ghrp-6
- Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor. Mol Endocrinol (2001). pmid:11518797
- Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab (1993). pmid:8473389
- Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab (1995). pmid:7883854
- Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro. Eur J Pharmacol (2005). pmid:15890336
- The effects of ghrelin antagonists [D-Lys(3) ]-GHRP-6 or JMV2959 on ethanol, water, and food intake in C57BL/6J mice. Alcohol Clin Exp Res (2014). pmid:25257292
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.